Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine

Phase 3

Active, not recruiting

• Conditions: Dengue
• Interventions: Other: Placebo; Biological: Dengue 1,2,3,4 (attenuated) vaccine

• Registration Number: NCT02406729
• Lead Sponsor: Butantan Institute

Brief Summary

This is a randomized, multicenter, double-blind, placebo-controlled Phase III study that will evaluate efficacy and safety of a live attenuated, tetravalent, lyophilized dengue vaccine produced by Butantan Institute.

The study will be carried out in multiple sites in Brazil. The study will be community-based in select urban areas where there's dengue transmission.

Study's intervention will be a single dose of the tetravalent dengue vaccine or placebo in a ratio 2:1. For efficacy analysis will be considered all dengue cases occurring after 28 days post-vaccination in the entire population of 16944 participants.

For safety analysis participants will be divided in three age groups: 18 to 59 ys, 7-17 ys and 2 to 6 ys. In each of these age groups there will be a minimum of 4992 participants. The age groups of 18 to 59 ys and 7 to 17 ys will start first. Once safety data for the first 21 days after vaccination is analysed for 450 participants in 7-to17-ys age group, the following group, of 2 to 6 ys, will start.

The study's hypothesis is that the vaccine under investigation and produced by Butantan Institute is safe and provides protection against dengue symptomatic disease of 80% or more with a lower bound of the 95% confidence interval of 25%. This way, the expected number of dengue cases virologically confirmed is 24 or more which will provide a response in terms of vaccine efficacy.

All participants will be followed up for five years to verify dengue incidence, regardless severity.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-03-30
• Study First Submitted QC: 2015-04-01
• Study First Posted: 2015-04-02
• Study Start: 2016-02-22
• Primary Completion: 2021-07-13
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-14
• Last Update Posted: 2024-02-15
• Study Completion: 2024-11

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 16935

Inclusion Criteria

1. Children who have completed 24 months of age, adolescents and adults who have not completed 60 years of age;
2. Agree with periodic contacts, either/or by phone, electronic means, and home visits.
3. Show voluntary intention to participate in the study, documented by the participant's or participant's legal representative's signature of the informed consent form.

Exclusion Criteria

1. For women: Pregnancy (confirmed by positive beta-hCG test) or breastfeeding;
2. Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as per clinical history and/or physical examination;
3. Compromised immune system diseases including: decompensated diabetes mellitus, cancer (except basal cell carcinoma), congenital or acquired immune deficiencies and not controlled autoimmune, as per clinical history and/or physical examination;
4. Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements;
5. Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history;
6. History of severe allergic reactions or anaphylaxis to the vaccine or to components of the vaccine in study;
7. History of asplenia;
8. Use of any investigational product within 28 days before or after receiving this study vaccination;
9. Has participated in another clinical trial six months prior to inclusion in the study or planning to participate in another clinical trial within 2 years following inclusion;
10. Use of immunosuppressant drugs such as: antineoplastic chemotherapy, radiation therapy, immunosuppressants to induce tolerance to transplants, and corticosteroids use (except topical or nasal). For this protocol will be considered for exclusion use of corticosteroids 3 months prior to the inclusion in the study and 6 months prior to the inclusion for the other therapies mentioned, and planned use of any immunosuppressant therapy within 2 years following inclusion in the study. It will be considered immunosuppressive dose of corticosteroids the equivalent to a dose ≥20 mg of prednisone per day for adults and the equivalent of prednisone at 2 mg/kg/day for children for over 7 days;
11. Have received blood products in the past three months, including transfusions or immunoglobulin, or scheduled administration of blood products or immunoglobulin for the following 2 years after vaccination;
12. Fever or suspected fever within 72 hours prior to vaccination or axillary temperature greater than 37,8°C on the day of vaccination (inclusion might be postponed until participant has completed 72 hours of no fever);
13. Have received live virus vaccine within 28 days or killed virus vaccine in the last 14 days prior to vaccination, or have a scheduled immunization during the first 28 days after receiving the investigational product;
14. Any other condition that might put in risk the safety/rights of a potential participant or hurdle his/her compliance with this protocol in investigator's opinion or his representative physician.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo Single dose, SC
Dengue 1,2,3,4 (attenuated) vaccine	Dengue 1,2,3,4 (attenuated) vaccine	Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC

Primary Outcome Measures

Name	Time	Method
Efficacy (incidence density of symptomatic dengue cases, virologically confirmed)	Five years post vaccination, all cases after 28 days post-vaccination	The primary efficacy outcome is incidence density of symptomatic dengue cases, virologically confirmed, after 28 days post-vaccination. Virological confirmation might be done by viral isolation, RT-PCR and/or detection of NS1.
Safety (adverse reactions)	In the first 21 days post-vaccination	The primary safety outcome is the frequency of local and systemic adverse reactions, solicited and non-solicited in the three age groups, within the first 21 days post-vaccination. Adverse reactions are defined as adverse events that have a reasonable causal relationship with vaccination.

Secondary Outcome Measures

Name	Time	Method
Efficacy (incidence density of dengue cases confirmed virologically, regarding the viral serotype)	Five years post vaccination, all cases after 28 days post-vaccination	The incidence density of dengue cases confirmed virologically after 28 days of vaccination, regarding the viral serotype. Virological diagnosis of the viral serotype will be performed using the viral isolation technique or RT-PCR.
Efficacy (incidence density of dengue cases confirmed virologically, regarding previous exposure to dengue viruses. )	at five years post vaccination, all cases after 28 days post-vaccination	The incidence density of dengue cases confirmed virologically after 28 days of vaccination, regarding previous exposure to dengue viruses. To demonstrate previous exposure or not to dengue viruses, validated serological methods such as: Elisa IgG Indirect, hemagglutination inhibition test or neutralizing antibodies (e.g., VRNT) or another validated test will be used. In case of doubtful results, more than one technique may be used to confirm the diagnosis.
Efficacy (incidence density of cases of severe dengue and/or with alarm signs, including cases hospitalized or not)	Five years post vaccination, all cases after 28 days post-vaccination	Incidence density of cases of severe dengue and/or with alarm signs, including cases hospitalized or not, after 28 days of vaccination. Laboratory confirmation of these cases will occur through serological and/or virological tests.
Safety ( frequency of solicited and unsolicited local and systemic adverse reactions in participants regarding previous exposure to dengue viruses )	In the first 21 days post-vaccination	The frequency of solicited and unsolicited local and systemic adverse reactions in participants regarding previous exposure to dengue viruses during the 21-day period after vaccination.
Immunogenicity (non-inferiority between simplified formulation vs. conventional formulation)	4 weeks post vaccination	The geometric mean of titers of neutralizing antibodies for each serotype at Week 4 postvaccination in a subgroup of adult participants without previous prior exposure to dengue and vaccinated with the conventional formulation and the simplified formulation of the dengue 1, 2, 3, 4 (attenuated) vaccine.
Safety (frequency of unsolicited adverse reactions)	Five years post vaccination, all cases after the first 21 days post-vaccination	The frequency of unsolicited adverse reactions after 21 days of vaccination until the end of the study.
Immunogenicity (consistency of the immune response to different batches of the vaccine )	4 weeks post vaccination	The geometric mean of neutralizing antibody titers for each serotype in the fourth week after vaccination in a subgroup of adult participants without previous exposure to dengue immunized with three consecutive batches of dengue vaccine 1,2,3,4 (attenuated).

Trial Locations

Locations (17)

Instituto de Infectologia Evandro Chagas - Fiocruz; 🇧🇷 Rio De Janeiro, Brazil

Faculdade de Medicina de São José do Rio Preto - FAMERP; 🇧🇷 São José Do Rio Preto, São Paulo, Brazil

Fundação de Medicina Tropical Doutor Heitor Vieira Dourado; 🇧🇷 Manaus, Amazonas, Brazil

Universidade de Brasília; 🇧🇷 Brasilia, DF, Brazil

Universidade Federal de Sergipe; 🇧🇷 Laranjeiras, SE, Brazil

Hospital Escola da Universidade Federal de Pelotas (HEUFPel); 🇧🇷 Pelotas, Rio Grande Do Sul, Brazil

Hospital Universitário Júlio Müller da Universidade Federal de Mato Grosso; 🇧🇷 Cuiabá, Mount, Brazil

Centro de Pesquisas em Medicina Tropical de Rondônia (CEPEM); 🇧🇷 Porto Velho, RO, Brazil

HCFMUSP; 🇧🇷 São Paulo, Brazil

Hospital São Lucas da Pontificia Universidade Catolica do Rio Grande do Sul; 🇧🇷 Porto Alegre, RS, Brazil

Universidade Federal do Ceará; 🇧🇷 Fortaleza, CE, Brazil

Universidade Federal de Minas Gerais; 🇧🇷 Belo Horizonte, MG, Brazil

Instituto Gonçalo Muniz - Fiocruz Bahia; 🇧🇷 Simões Filho, BA, Brazil

Universidade Federal de Mato Grosso do Sul; 🇧🇷 Campo Grande, MS, Brazil

Santa Casa de Misericórdia de São Paulo - CSEBF; 🇧🇷 São Paulo, SP, Brazil

Universidade Federal de Roraima - UFRR; 🇧🇷 Boa Vista, Roraima, Brazil

Centro de Pesquisas Aggeu Magalhães - Fiocruz Pernambuco; 🇧🇷 Recife, Pernambuco, Brazil